AbbVie (ABBV) — Company Research
Last Updated: 1 June 2026
AbbVie Inc. (NYSE: ABBV) is a research-based biopharmaceutical company spun out of Abbott Laboratories in 2013. Once almost wholly dependent on the immunology blockbuster Humira, AbbVie has executed one of the most closely watched patent-cliff transitions in the industry: two next-generation immunology drugs, Skyrizi and Rinvoq, have more than replaced Humira's lost revenue, while neuroscience, oncology and aesthetics provide diversification. This report reviews AbbVie's full-year 2025 results and first-quarter 2026 update using only company filings and press releases.
1. Company Snapshot
| Field | Value |
|---|---|
| Ticker | NYSE: ABBV |
| Sector / Industry | Healthcare — Pharmaceuticals |
| Headquarters | North Chicago, Illinois, USA |
| Founded | 2013 (spun off from Abbott Laboratories) |
| Employees | Approximately 57,000 |
| CEO / Leadership | Robert A. Michael (Chief Executive Officer, since July 2024); Richard A. Gonzalez (Executive Chairman) |
| Market cap | ~$383 billion (late May 2026) |
| FY2025 revenue | $61.16 billion |
| FY2025 net earnings (GAAP) | $4.23 billion |
| FY2025 GAAP diluted EPS | $2.36 |
| FY2025 adjusted diluted EPS | $10.00 |
| Dividend (annualised) | $6.92 per share ($1.73 quarterly); ~3.2% yield |
| 52-week range | $181.73 – $244.81 |
2. Bull and Bear Case
Bull Case
- Skyrizi and Rinvoq momentum: The two drugs delivered combined 2025 revenue of about $25.9bn (Skyrizi $17.6bn, Rinvoq $8.3bn) and are still growing rapidly, more than offsetting Humira's decline.
- Successful Humira transition: Despite biosimilar erosion that cut Humira to $4.5bn, total revenue grew 8.6% in 2025, demonstrating the diversification is working.
- Diversified growth platforms: Neuroscience grew ~20% to $10.8bn and oncology and aesthetics add further breadth beyond immunology.
- Strong cash and rising dividend: AbbVie generated roughly $17.8bn of free cash flow in 2025 and raised the dividend again for 2026 to $1.73 per quarter, a ~3.2% yield.
- Raised 2026 outlook: After a strong first quarter, management lifted FY2026 adjusted EPS guidance to $14.08–14.28.
Bear Case
- High leverage: AbbVie carries roughly $67bn of total debt against only ~$5bn of cash, a legacy of the $63bn Allergan acquisition.
- Concentration shift: Skyrizi and Rinvoq now anchor the business; their growth slowing or facing competition would matter greatly.
- GAAP earnings volatility: Large acquired-IPR&D, contingent-consideration and amortisation charges keep GAAP EPS far below adjusted EPS ($2.36 versus $10.00 in 2025).
- Aesthetics softness: The Botox Cosmetic and Juvederm franchise fell ~6% in 2025 as discretionary spending weakened.
- Pricing and policy: Medicare negotiation and broader drug-pricing pressure are headwinds for the US portfolio.
3. Business Segments
AbbVie reports as a single operating segment; the figures below show its main therapeutic portfolios for full-year 2025.
| Segment | % of revenue | What it is |
|---|---|---|
| Immunology | ~49.7% | Skyrizi ($17.6bn) and Rinvoq ($8.3bn) plus declining Humira ($4.5bn), treating psoriasis, IBD and rheumatology. FY2025 $30.4bn. |
| Neuroscience | ~17.6% | Vraylar, Botox Therapeutic, the Ubrelvy/Qulipta migraine franchise and Vyalev for Parkinson's. FY2025 $10.8bn. |
| Eye care & other | ~13.9% | Eye care, established products and other key products. FY2025 $8.5bn. |
| Oncology | ~10.9% | Imbruvica, Venclexta and Elahere across haematology and solid tumours. FY2025 $6.7bn. |
| Aesthetics | ~7.9% | Botox Cosmetic and Juvederm dermal fillers (Allergan Aesthetics). FY2025 $4.9bn. |
4. Business Model and Moat
How it makes money. AbbVie discovers, develops, manufactures and sells branded prescription medicines and aesthetic products worldwide. The overwhelming majority of revenue and profit comes from a handful of high-priced specialty drugs — principally the immunology pair Skyrizi and Rinvoq — sold through specialty pharmacies and physician channels in immunology, neuroscience and oncology, supplemented by cash-pay aesthetics.
The moat. AbbVie's advantage rests on patent-protected biologics and small molecules, deep payer and prescriber relationships, and the commercial scale built around Humira and now extended to its successors. Switching costs for chronically treated patients, a broad clinical-trial footprint, and the Allergan-derived aesthetics brands (Botox, Juvederm) reinforce durability.
Unit economics. Specialty drugs carry high gross margins, funding heavy reinvestment: research and development was $9.1bn in 2025 and the company also spent $5.0bn on acquired IPR&D and milestones. Free cash flow of roughly $17.8bn comfortably covers the dividend and debt service.
5. Financial Health
Full-year figures are from AbbVie's audited results and quarterly press releases. Revenue is shown in US dollars. GAAP EPS is well below adjusted EPS because of large intangible-amortisation, acquired-IPR&D and contingent-consideration charges.
| Year | Revenue ($m) | YoY % | GAAP EPS | Adjusted EPS | Dividend/share | Long-term debt (YE, $bn) |
|---|---|---|---|---|---|---|
| 2021 | 56,197 | — | 6.45 | 12.70 | 5.20 | — |
| 2022 | 58,054 | +3.3% | 6.63 | 13.77 | 5.64 | 59.1 |
| 2023 | 54,318 | -6.4% | 2.72 | 11.11 | 5.92 | 52.2 |
| 2024 | 56,334 | +3.7% | 2.39 | 10.12 | 6.20 | — |
| 2025 | 61,160 | +8.6% | 2.36 | 10.00 | 6.56 | 58.9 |
For FY2025, cost of products sold was $18.20bn, selling, general and administrative expense $14.01bn, research and development $9.10bn, and acquired IPR&D and milestones $5.02bn; operating earnings were $15.08bn and net earnings attributable to AbbVie were $4.23bn. Intangible asset amortisation was $7.38bn. At 31 December 2025 long-term debt was $58.9bn (with a further $6.1bn current portion and $2.5bn short-term borrowings, ~$67.5bn total debt) against $5.2bn of cash. Operating cash flow was roughly $19.0bn and capital expenditure ~$1.2bn, giving free cash flow of about $17.8bn. The quarterly table shows the most recent periods first with the full-year 2025 total in bold.
| Quarter | Revenue | Adjusted EPS | GAAP EPS |
|---|---|---|---|
| Q1 2026 | $15.00bn | $2.65 | $0.39 |
| Q4 2025 | $16.62bn | $2.71 | $1.02 |
| Q3 2025 | $15.78bn | $1.86 | $0.10 |
| Q2 2025 | $15.42bn | $2.97 | $0.52 |
| Q1 2025 | $13.34bn | $2.46 | $0.72 |
| FY 2025 | $61.16bn | $10.00 | $2.36 |
6. Valuation
Raw metrics, May 2026. Not opinions on whether the stock is cheap or expensive.
| Metric | Value |
|---|---|
| Market cap | ~$383bn |
| Trailing P/E (GAAP) | ~92x (price ~$217 / FY2025 GAAP EPS $2.36; GAAP EPS is heavily depressed by $2.76 per share of acquired IPR&D plus large contingent-consideration and intangible-amortisation charges) |
| P/E (forward) | ~15.3x (price ~$217 / FY2026 adjusted EPS guidance midpoint ~$14.18) |
| P/S (TTM) | ~6.3x (market cap ~$383bn / FY2025 net revenues $61.16bn) |
| EV/EBITDA (TTM) | ~19.2x (EV ~$445bn / GAAP EBITDA ~$23.2bn; EBITDA ≈ operating earnings $15.08bn + intangible amortisation $7.38bn + depreciation ~$0.75bn; GAAP EBITDA is depressed by ~$5.0bn of acquired IPR&D and ~$0.85bn of impairment) |
| P/FCF | ~21.5x (market cap ~$383bn / FCF ~$17.8bn; FCF = operating cash flow ~$19.0bn − capex ~$1.2bn per FY2025) |
| Enterprise value | ~$445bn (market cap ~$383bn + total debt ~$67.5bn − cash ~$5.2bn per 31 Dec 2025 balance sheet) |
| 52-week high | $244.81 |
| 52-week low | $181.73 |
| Short interest (% of float) | ~1.12% (~19.7m shares short, early 2026) |
| Days to cover | ~2.77 |
7. Growth Drivers
AbbVie's growth is led by Skyrizi and Rinvoq, which continue to gain share across psoriasis, inflammatory bowel disease and rheumatology, supported by a steady stream of new indications — including a pending Skyrizi subcutaneous induction filing in Crohn's disease and a Rinvoq submission in vitiligo that, if approved, would be the first systemic treatment for the condition. Neuroscience is a second engine, with Vraylar, the Ubrelvy/Qulipta migraine franchise and Vyalev for Parkinson's driving roughly 20% growth. Oncology (Imbruvica, Venclexta, Elahere) and the cash-pay aesthetics portfolio add diversification, while bolt-on deals such as the 2025 acquisition of Capstan Therapeutics extend the immunology pipeline into in vivo CAR-T. Management's strategy is to layer durable, patent-protected growth on top of the Skyrizi/Rinvoq base so the company can keep growing through the rest of the decade.
8. Peer Comparison
AbbVie competes with the other global large-cap drug makers, most directly in immunology. Market caps are approximate, as of June 2026.
| Peer | Market cap (Jun 2026) | Key 2025 metric |
|---|---|---|
| Eli Lilly (LLY) | >$1.0tn | Industry's most valuable company; obesity/incretin leader |
| Johnson & Johnson (JNJ) | ~$565bn | Immunology competitor (Tremfya, Stelara) plus medtech |
| Merck (MRK) | ~$302bn | FY2025 sales $65.0bn; Keytruda $31.7bn |
| AstraZeneca (AZN) | ~$291bn | Oncology-led global biopharma |
9. Insider Activity
No insider transactions of note (open-market purchases or sales) were identified in AbbVie's recent Form 4 filings for the period reviewed; activity was limited to routine equity-plan grants and related awards. Chief Executive Officer Robert A. Michael continues to lead the company, with Richard A. Gonzalez as Executive Chairman.
10. Key Risks
- Leverage and refinancing (Financial): Roughly $67bn of total debt against ~$5bn of cash leaves limited balance-sheet flexibility and exposure to refinancing costs.
- Key-product concentration (Operational): Skyrizi and Rinvoq now drive the business; any growth slowdown, safety signal or new competition would be material.
- Drug-pricing and policy (Regulatory): Medicare price negotiation and broader US pricing pressure threaten net revenue on key products.
- Aesthetics cyclicality (Macro): Botox Cosmetic and Juvederm are discretionary cash-pay products sensitive to economic conditions, and fell ~6% in 2025.
- Pipeline and M&A risk (Operational): Sustained growth depends on pipeline success and on integrating acquisitions such as Capstan and Cerevel-derived assets.
- Earnings quality (Financial): Large IPR&D, contingent-consideration and amortisation charges keep GAAP earnings far below adjusted earnings.
11. Recent Developments
- 29 Apr 2026 — Q1 2026 results. Net revenues rose 12.4% to $15.00bn and adjusted EPS was $2.65 (GAAP $0.39); Skyrizi reached $4.48bn and Rinvoq $2.12bn, and FY2026 adjusted EPS guidance was raised to $14.08–14.28.
- 17 Feb 2026 — dividend increase. AbbVie's increased quarterly dividend of $1.73 per share (up from $1.64) became payable, lifting the annualised rate to $6.92.
- 04 Feb 2026 — Q4 and full-year 2025 results. Full-year net revenues were $61.16bn (up 8.6%); adjusted EPS was $10.00 and GAAP EPS $2.36; immunology reached $30.4bn with Skyrizi at $17.6bn.
- 19 Aug 2025 — Capstan Therapeutics acquisition completed. AbbVie completed its acquisition of Capstan, adding the Phase 1 in vivo CAR-T candidate CPTX2309 for B-cell-mediated autoimmune diseases.
12. Key Dates
- 30 Jul 2026 — expected second-quarter 2026 earnings release (based on prior-year timing)
- 15 Aug 2026 — approximate quarterly dividend payment date ($1.73 per share)
- 06 Feb 2027 — expected fourth-quarter and full-year 2026 results (based on prior-year timing)
Follow live pricing on ChartsView Live Charts, check the Economic Calendar, and join the discussion in the ChartsView Forum.
Disclaimer: This research is produced by ChartsView for educational and informational purposes only. It does not constitute financial advice or a recommendation to buy or sell any security. All information is sourced from publicly available company filings, press releases, and official data. ChartsView does not use analyst opinions or third-party ratings. Always conduct your own due diligence and consider your personal financial situation before making investment decisions. Past performance is not indicative of future results.
Loading research report…
13. Thesis Verdict
The central thesis. AbbVie is a specialty biopharmaceutical company whose profit comes mainly from high-priced immunology drugs, now led by Skyrizi and Rinvoq, with further revenue from neuroscience, oncology and cash-pay aesthetics. Full-year 2025 net revenues were $61.16bn (up 8.6%) with adjusted EPS of $10.00, and after a strong first quarter management raised 2026 adjusted EPS guidance to $14.08–14.28. The defining driver is the continued rapid growth of Skyrizi and Rinvoq, which have more than replaced Humira’s biosimilar-eroded revenue.
What would confirm or break it. Sustained double-digit growth from Skyrizi and Rinvoq, new indication approvals and steady free-cash-flow-funded dividend growth would confirm the thesis. It would be undermined by a slowdown or competitive threat to the two lead drugs, pressure on the heavily leveraged balance sheet, or adverse drug-pricing outcomes that erode US net revenue.
Watchpoints
- ConfirmsQ2 2026 earnings (59 days) landing in line with or above management guidance.
- ConfirmsEvidence supporting the "Skyrizi and Rinvoq momentum:" thesis continuing to build across subsequent filings.
- InvalidatesMaterialisation of the "Leverage and refinancing (Financial):" risk, or any disclosure that fundamentally alters the capital-return or growth profile stated by management.
Diagnostic grid
Generated by ChartsView research tooling. Thesis strength measures how well the evidence in this report supports the company's stated thesis — it is NOT a buy/sell rating or price target. ChartsView is not authorised by the FCA to provide regulated investment advice. Generated 1 Jun 2026.